$10.64
-0.02(-0.19%)
Mkt Cap $196M
$4.76
$13.84
52-Week Range
At a Glance
AI-generatedElicio Therapeutics, Inc.
8-K
Elicio Therapeutics, Inc. entered into an At Market Issuance Sales Agreement on March 16, 2026, with B. Riley Securities, Inc., JonesTrading Institutional Services LLC, and Ladenburg Thalmann & Co. Inc. to issue and sell up to $100.0 million of common stock through an at-the-market offering program. The company simultaneously terminated its prior Capital on Demand Sales Agreement with JonesTrading, which had a $40.0 million capacity and no termination penalties.$196M
Market Cap
—
Revenue
-$48M
Net Income
Employees32
Fundamentals
How The Business Makes Money
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001601485
ISINUS28657F1030
CUSIP28657F103
Phone857-209-0050
Address451 D Street, Boston, MA, 02210, US
SEC EDGAR